The systemic amyloidoses
JN Buxbaum - Current opinion in rheumatology, 2004 - journals.lww.com
JN Buxbaum
Current opinion in rheumatology, 2004•journals.lww.comTherapies have been proposed based on precursor stabilization (transthyretin), elimination
of the synthesizing cell (light-chain amyloid), fibril disruption and immunization to induce
host-mediated aggregate clearance (Alzheimer disease, light-chain amyloid, prions), and
aggressive therapy of a primary inflammatory process (amyloid A). During the next decade,
the value of these therapies, and others, suggested by studies on the basic properties of
cells and proteins, will become clear.
of the synthesizing cell (light-chain amyloid), fibril disruption and immunization to induce
host-mediated aggregate clearance (Alzheimer disease, light-chain amyloid, prions), and
aggressive therapy of a primary inflammatory process (amyloid A). During the next decade,
the value of these therapies, and others, suggested by studies on the basic properties of
cells and proteins, will become clear.
Summary
Therapies have been proposed based on precursor stabilization (transthyretin), elimination of the synthesizing cell (light-chain amyloid), fibril disruption and immunization to induce host-mediated aggregate clearance (Alzheimer disease, light-chain amyloid, prions), and aggressive therapy of a primary inflammatory process (amyloid A). During the next decade, the value of these therapies, and others, suggested by studies on the basic properties of cells and proteins, will become clear.
Lippincott Williams & Wilkins